US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Intensity Therapeutics, Inc.

4.53

-0.3650-7.46%

Post-market: 4.770.2400+5.30%16:37 EDT

Volume:126.26K

Turnover:590.24K

Market Cap:14.79M

PE:-0.94

High:5.08

Open:4.83

Low:4.36

Close:4.90

52wk High:43.50

52wk Low:3.51

Shares:3.26M

Float Shares:3.04M

Volume Ratio:2.66

T/O Rate:4.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.8026

EPS(LYR):-8.5567

ROE:-195.88%

ROA:-89.91%

PB:1.61

PE(LYR):-0.53

Loading ...

Overview Company News Filings

Intensity Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $7 from $5

THOMSON REUTERS

Oncology Firm Immunome's Q2 Net Loss Widens as R&D Costs Rise

Erasca Q2 Net Loss Widens on Higher R&D Costs

Intensity Therapeutics Q2 Operating Income USD -3.084 Million

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS

Intensity Therapeutics Q2 Basic EPS USD -1.11

THOMSON REUTERS

Intensity Therapeutics Q2 FY26 Net Loss Widens 18.53% to $3.01 Million

Intensity Therapeutics Schedules Q2 Financial Results Conference Call

Intensity Therapeutics provides update in Invincicle-4 study

Intensity Therapeutics Restarts Phase 2 Invincible-4 Breast Cancer Trial, Doses First Patients in Switzerland

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (invincible-4 Study)

THOMSON REUTERS

Intensity Therapeutics Targets Strategic Partnerships to Accelerate Int230-6 Development

Intensity Therapeutics Resumes Enrollment in Phase 3 Int230-6 Soft Tissue Sarcoma Trial

Intensity Therapeutics - Advances Late-stage Clinical Studies in Soft Tissue Sarcoma and Presurgical Triple-negative Breast Cancer

THOMSON REUTERS

Intensity Therapeutics Provides Mid-year Update Highlighting Late-stage Development Programs and Strategic Partnering Opportunities for Int230-6

THOMSON REUTERS

Intensity Therapeutics - over 200 Patients Enrolled in Completed Int230-6 Studies with Peer-reviewed Publication

THOMSON REUTERS

Intensity Therapeutics held annual shareholder meeting via webcast

Intensity Therapeutics Q1 FY26 net loss narrows to $2.4 million

BRIEF-Intensity Therapeutics Q1 Operating Income USD -2.526 Million

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/INTS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"INTS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INTS\",,,,,undefined,":{"symbol":"INTS","market":"US","secType":"STK","nameCN":"Intensity Therapeutics, Inc.","latestPrice":4.53,"timestamp":1787774400000,"preClose":4.895,"halted":0,"volume":126261,"hourTrading":{"tag":"盘后","latestPrice":4.77,"preClose":4.53,"latestTime":"16:37 EDT","volume":1915,"amount":8827.9904805,"timestamp":1787776656571,"change":0.24,"changeRate":0.05298,"amplitude":0.05298},"delay":0,"changeRate":-0.07456588355464747,"floatShares":3038900,"shares":3264900,"eps":-4.802551,"marketStatus":"Post-Mkt","change":-0.365,"latestTime":"08-26 18:07:26 EDT","open":4.83,"high":5.075,"low":4.36,"amount":590243.9505903,"amplitude":0.146067,"askPrice":5.18,"askSize":150,"bidPrice":4.32,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-4.802551,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787788800000},"marketStatusCode":4,"adr":0,"listingDate":1666324800000,"exchange":"NASDAQ","adjPreClose":4.895,"preHourTrading":{"tag":"盘前","latestPrice":5,"preClose":4.895,"latestTime":"09:14 EDT","volume":3813,"amount":19273.6599429,"timestamp":1787750097870,"change":0.105,"changeRate":0.02145,"amplitude":0.053115},"postHourTrading":{"tag":"盘后","latestPrice":4.77,"preClose":4.53,"latestTime":"16:37 EDT","volume":1915,"amount":8827.9904805,"timestamp":1787776656571,"change":0.24,"changeRate":0.05298,"amplitude":0.05298},"volumeRatio":2.663442},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INTS\",,,,,undefined,":{"symbol":"INTS","floatShares":3038900,"roa":"-89.91%","roe":"-195.88%","lyrEps":-8.556737,"volumeRatio":2.663442,"shares":3264900,"dividePrice":0,"high":5.075,"amplitude":0.146067,"preClose":4.895,"low":4.36,"week52Low":3.51,"pbRate":"1.61","week52High":43.5,"institutionHeld":0,"latestPrice":4.53,"committee":-0.973684,"eps":-4.802551,"divideRate":0,"volume":126261,"delay":0,"ttmEps":-4.802551,"open":4.83,"prevYearClose":10.255,"prevWeekClose":4.86,"prevMonthClose":4.15,"prevQuarterClose":4.1,"fiveDayClose":4.2,"twentyDayClose":4.33,"sixtyDayClose":4.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INTS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"INTS","fiscalQuarterEnding":"2026/06","expectedEps":-0.81,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-1.11},{"market":"US","date":"2026-02-19","symbol":"INTS","defaultRemindTime":1771511400000,"type":"split","dateTimestamp":1771477200000,"forFactor":25,"toFactor":1,"ratio":25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INTS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INTS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":5,"updateTime":1774929600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/INTS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"INTS","date":"2026-08-25","current":-1.01925,"percent":0.682353,"low":-15.25821,"twenty":-5.424948,"median":-2.151584,"eighty":-1.104508,"high":-0.31723,"avg":-3.551473,"sd":3.166365,"marketCap":15508175},"quantilePoints":[{"date":"2022-10-20","current":-9.173693,"twenty":-9.173693,"median":-9.173693,"eighty":-9.173693,"marketCap":80934718},{"date":"2023-07-07","current":-12.000673,"twenty":-12.000673,"median":-11.893737,"eighty":-9.173693,"marketCap":78596262},{"date":"2023-07-14","current":-11.805305,"twenty":-12.014248,"median":-11.893737,"eighty":-11.600651,"marketCap":77316730},{"date":"2023-07-21","current":-12.682867,"twenty":-12.306769,"median":-11.947205,"eighty":-11.660654,"marketCap":83064168},{"date":"2023-07-28","current":-11.867988,"twenty":-12.682867,"median":-12.014248,"eighty":-11.805305,"marketCap":77727261},{"date":"2023-08-04","current":-12.81868,"twenty":-12.682867,"median":-12.066484,"eighty":-11.867988,"marketCap":83953652},{"date":"2023-08-11","current":-12.933599,"twenty":-12.933599,"median":-12.306769,"eighty":-11.888882,"marketCap":84706293},{"date":"2023-08-18","current":-9.652146,"twenty":-12.81868,"median":-12.1197,"eighty":-11.660654,"marketCap":80327292},{"date":"2023-08-25","current":-9.800135,"twenty":-12.808233,"median":-12.000673,"eighty":-9.800135,"marketCap":81558886},{"date":"2023-09-01","current":-9.487714,"twenty":-12.770623,"median":-11.912204,"eighty":-9.783692,"marketCap":78958855},{"date":"2023-09-08","current":-9.093078,"twenty":-12.755579,"median":-11.893737,"eighty":-9.638992,"marketCap":75674604},{"date":"2023-09-15","current":-8.073601,"twenty":-12.70794,"median":-11.836647,"eighty":-9.487714,"marketCap":67190291},{"date":"2023-09-22","current":-6.034647,"twenty":-12.632721,"median":-11.600651,"eighty":-9.000996,"marketCap":50221663},{"date":"2023-09-29","current":-6.626601,"twenty":-12.586753,"median":-9.923459,"eighty":-8.293939,"marketCap":55148039},{"date":"2023-10-06","current":-7.251442,"twenty":-12.570873,"median":-9.800135,"eighty":-7.560574,"marketCap":60348102},{"date":"2023-10-13","current":-6.626601,"twenty":-12.448015,"median":-9.783692,"eighty":-7.192246,"marketCap":55148039},{"date":"2023-10-20","current":-4.636976,"twenty":-12.331842,"median":-9.61926,"eighty":-6.745518,"marketCap":38589943},{"date":"2023-10-23","current":-4.96584,"twenty":-12.319306,"median":-9.578152,"eighty":-6.686849,"marketCap":41326818},{"date":"2023-11-03","current":-4.932954,"twenty":-12.157898,"median":-9.487714,"eighty":-6.567406,"marketCap":41053131},{"date":"2023-11-10","current":-4.609845,"twenty":-12.119112,"median":-9.173693,"eighty":-6.48519,"marketCap":38364150},{"date":"2023-11-17","current":-3.237228,"twenty":-12.035142,"median":-8.862874,"eighty":-6.287872,"marketCap":28737191},{"date":"2023-11-24","current":-3.590621,"twenty":-12.006103,"median":-8.517567,"eighty":-5.189368,"marketCap":31874301},{"date":"2023-12-01","current":-3.784438,"twenty":-11.971208,"median":-8.209257,"eighty":-5.01517,"marketCap":33594828},{"date":"2023-12-08","current":-6.177413,"twenty":-11.939029,"median":-7.613192,"eighty":-5.01517,"marketCap":54837508},{"date":"2023-12-15","current":-12.447487,"twenty":-12.056037,"median":-8.209257,"eighty":-5.034902,"marketCap":110497578},{"date":"2023-12-22","current":-9.544103,"twenty":-12.056037,"median":-8.517567,"eighty":-5.074891,"marketCap":84723949},{"date":"2023-12-29","current":-12.200391,"twenty":-12.097826,"median":-8.854652,"eighty":-5.093498,"marketCap":108304078},{"date":"2024-01-05","current":-12.586479,"twenty":-12.221667,"median":-9.093078,"eighty":-5.095649,"marketCap":111731422},{"date":"2024-01-12","current":-9.080797,"twenty":-12.136622,"median":-9.173576,"eighty":-5.162954,"marketCap":80611136},{"date":"2024-01-19","current":-7.443783,"twenty":-12.119504,"median":-9.086938,"eighty":-5.189368,"marketCap":66079197},{"date":"2024-01-26","current":-6.94959,"twenty":-12.056037,"median":-8.862874,"eighty":-5.265897,"marketCap":61692196},{"date":"2024-02-02","current":-7.706323,"twenty":-12.006103,"median":-8.582973,"eighty":-5.358906,"marketCap":68409791},{"date":"2024-02-09","current":-5.497898,"twenty":-11.971208,"median":-8.279141,"eighty":-5.454656,"marketCap":48805382},{"date":"2024-02-16","current":-4.67939,"twenty":-11.939029,"median":-8.106172,"eighty":-5.189368,"marketCap":41539412},{"date":"2024-02-23","current":-4.63306,"twenty":-11.915897,"median":-7.791263,"eighty":-5.065946,"marketCap":41128131},{"date":"2024-03-01","current":-5.714107,"twenty":-11.893737,"median":-7.613192,"eighty":-5.065946,"marketCap":50724694},{"date":"2024-03-08","current":-8.617491,"twenty":-11.891795,"median":-7.659757,"eighty":-5.094215,"marketCap":76498323},{"date":"2024-03-15","current":-6.42451,"twenty":-11.880524,"median":-7.613192,"eighty":-5.12966,"marketCap":57031008},{"date":"2024-03-22","current":-7.168217,"twenty":-11.842915,"median":-7.462714,"eighty":-5.183371,"marketCap":75538667},{"date":"2024-03-28","current":-6.569781,"twenty":-11.793205,"median":-7.382998,"eighty":-5.190398,"marketCap":69232353},{"date":"2024-04-05","current":-6.062412,"twenty":-11.727976,"median":-7.320234,"eighty":-5.219219,"marketCap":63885696},{"date":"2024-04-12","current":-5.919308,"twenty":-11.648653,"median":-7.270395,"eighty":-5.328019,"marketCap":62377665},{"date":"2024-04-19","current":-4.956607,"twenty":-11.467325,"median":-7.168217,"eighty":-5.219219,"marketCap":52232726},{"date":"2024-04-26","current":-5.106216,"twenty":-10.872247,"median":-7.057617,"eighty":-5.181486,"marketCap":53809304},{"date":"2024-05-03","current":-5.203787,"twenty":-10.575732,"median":-7.004794,"eighty":-5.110119,"marketCap":54837508},{"date":"2024-05-10","current":-4.89156,"twenty":-10.334812,"median":-6.920091,"eighty":-5.07751,"marketCap":51547257},{"date":"2024-05-17","current":-5.064674,"twenty":-10.138832,"median":-6.816961,"eighty":-5.04775,"marketCap":69917822},{"date":"2024-05-24","current":-5.034882,"twenty":-10.040205,"median":-6.769756,"eighty":-5.01517,"marketCap":69506541},{"date":"2024-05-31","current":-4.905782,"twenty":-10.013896,"median":-6.720408,"eighty":-4.982612,"marketCap":67724322},{"date":"2024-06-07","current":-4.945811,"twenty":-9.945635,"median":-6.626601,"eighty":-4.965367,"marketCap":68276920},{"date":"2024-06-14","current":-4.747756,"twenty":-9.859151,"median":-6.577272,"eighty":-4.943699,"marketCap":65542772},{"date":"2024-06-21","current":-4.638498,"twenty":-9.834825,"median":-6.527942,"eighty":-4.905297,"marketCap":64034465},{"date":"2024-06-28","current":-4.887408,"twenty":-9.833021,"median":-6.527942,"eighty":-4.896744,"marketCap":67470661},{"date":"2024-07-05","current":-4.817184,"twenty":-9.806712,"median":-6.504734,"eighty":-4.887289,"marketCap":66501232},{"date":"2024-07-12","current":-4.986137,"twenty":-9.800135,"median":-6.468725,"eighty":-4.878216,"marketCap":68833622},{"date":"2024-07-15","current":-5.055665,"twenty":-9.800135,"median":-6.445726,"eighty":-4.87855,"marketCap":69793453},{"date":"2024-08-02","current":-4.807351,"twenty":-9.796846,"median":-6.435118,"eighty":-4.877213,"marketCap":66365484},{"date":"2024-08-09","current":-4.588835,"twenty":-9.783692,"median":-6.41284,"eighty":-4.86516,"marketCap":63348871},{"date":"2024-08-16","current":-3.955696,"twenty":-9.783692,"median":-6.339457,"eighty":-4.820512,"marketCap":59632119},{"date":"2024-08-23","current":-3.896315,"twenty":-9.757383,"median":-6.270563,"eighty":-4.807351,"marketCap":58736948},{"date":"2024-08-30","current":-3.86434,"twenty":-9.645569,"median":-6.204474,"eighty":-4.781352,"marketCap":58254933},{"date":"2024-09-06","current":-3.910018,"twenty":-9.61926,"median":-6.112191,"eighty":-4.747756,"marketCap":58943526},{"date":"2024-09-13","current":-3.837391,"twenty":-9.544103,"median":-6.034647,"eighty":-4.707926,"marketCap":57848664},{"date":"2024-09-20","current":-3.727307,"twenty":-9.537044,"median":-5.97785,"eighty":-4.668296,"marketCap":56189156},{"date":"2024-09-27","current":-3.316207,"twenty":-9.52866,"median":-5.925812,"eighty":-4.63306,"marketCap":49991822},{"date":"2024-10-04","current":-3.2888,"twenty":-9.487714,"median":-5.784184,"eighty":-4.588835,"marketCap":49578667},{"date":"2024-10-11","current":-3.037299,"twenty":-9.487714,"median":-5.559672,"eighty":-4.472545,"marketCap":45787276},{"date":"2024-10-18","current":-2.923378,"twenty":-9.487714,"median":-5.461423,"eighty":-4.216084,"marketCap":44069926},{"date":"2024-10-25","current":-2.923378,"twenty":-9.26612,"median":-5.333882,"eighty":-3.973967,"marketCap":44069926},{"date":"2024-10-31","current":-2.786345,"twenty":-9.192178,"median":-5.307863,"eighty":-3.960154,"marketCap":42004148},{"date":"2024-11-08","current":-2.941649,"twenty":-9.173693,"median":-5.199834,"eighty":-3.926462,"marketCap":44345363},{"date":"2024-11-15","current":-2.689442,"twenty":-9.173505,"median":-5.189027,"eighty":-3.893574,"marketCap":43725630},{"date":"2024-11-22","current":-2.507825,"twenty":-9.109154,"median":-5.115973,"eighty":-3.863938,"marketCap":40772862},{"date":"2024-11-29","current":-2.717615,"twenty":-9.085709,"median":-5.101291,"eighty":-3.84881,"marketCap":44185701},{"date":"2024-12-06","current":-2.321954,"twenty":-9.052999,"median":-5.073692,"eighty":-3.799491,"marketCap":37752650},{"date":"2024-12-13","current":-1.917562,"twenty":-8.931511,"median":-5.06017,"eighty":-3.723653,"marketCap":31177648},{"date":"2024-12-20","current":-1.857563,"twenty":-8.853008,"median":-5.047673,"eighty":-3.619065,"marketCap":30202120},{"date":"2024-12-27","current":-1.764685,"twenty":-8.767209,"median":-5.021654,"eighty":-3.573099,"marketCap":28692014},{"date":"2025-01-03","current":-1.625368,"twenty":-8.642201,"median":-5.01517,"eighty":-3.513045,"marketCap":26426855},{"date":"2025-01-10","current":-1.838802,"twenty":-8.617491,"median":-5.008645,"eighty":-3.463472,"marketCap":29897078},{"date":"2025-01-17","current":-2.572725,"twenty":-8.517567,"median":-4.984374,"eighty":-3.373331,"marketCap":41829936},{"date":"2025-01-24","current":-2.370715,"twenty":-8.346557,"median":-4.965604,"eighty":-3.310726,"marketCap":38545455},{"date":"2025-01-31","current":-2.053117,"twenty":-8.284074,"median":-4.956607,"eighty":-3.212827,"marketCap":33381630},{"date":"2025-02-07","current":-2.238919,"twenty":-8.253306,"median":-4.940989,"eighty":-3.06772,"marketCap":36402592},{"date":"2025-02-14","current":-2.015957,"twenty":-8.160869,"median":-4.905782,"eighty":-3.026792,"marketCap":32777437},{"date":"2025-02-21","current":-2.043827,"twenty":-8.138995,"median":-4.896744,"eighty":-3.006493,"marketCap":33230582},{"date":"2025-02-28","current":-2.099568,"twenty":-8.099657,"median":-4.889484,"eighty":-2.934341,"marketCap":34136870},{"date":"2025-03-07","current":-2.146018,"twenty":-8.038556,"median":-4.87855,"eighty":-2.919724,"marketCap":34892111},{"date":"2025-03-14","current":-2.159953,"twenty":-8.005927,"median":-4.871913,"eighty":-2.813752,"marketCap":35118683},{"date":"2025-03-21","current":-1.801034,"twenty":-7.907089,"median":-4.866947,"eighty":-2.682321,"marketCap":29299223},{"date":"2025-03-28","current":-1.800101,"twenty":-7.780452,"median":-4.846639,"eighty":-2.622879,"marketCap":29284042},{"date":"2025-04-04","current":-1.82903,"twenty":-7.718678,"median":-4.817184,"eighty":-2.548971,"marketCap":29754652},{"date":"2025-04-11","current":-1.810366,"twenty":-7.669259,"median":-4.807351,"eighty":-2.494707,"marketCap":29451033},{"date":"2025-04-17","current":-1.735712,"twenty":-7.632006,"median":-4.806913,"eighty":-2.414832,"marketCap":28236557},{"date":"2025-04-25","current":-0.839954,"twenty":-7.607202,"median":-4.796544,"eighty":-2.376882,"marketCap":13664368},{"date":"2025-05-02","current":-0.521647,"twenty":-7.551589,"median":-4.752722,"eighty":-2.245719,"marketCap":8486148},{"date":"2025-05-09","current":-0.530045,"twenty":-7.466501,"median":-4.747756,"eighty":-2.177388,"marketCap":8622776},{"date":"2025-05-16","current":-0.505526,"twenty":-7.426042,"median":-4.707976,"eighty":-2.157166,"marketCap":7588954},{"date":"2025-05-23","current":-0.365063,"twenty":-7.386285,"median":-4.686306,"eighty":-2.149257,"marketCap":5480321},{"date":"2025-05-30","current":-0.393378,"twenty":-7.360388,"median":-4.668296,"eighty":-2.119771,"marketCap":5905387},{"date":"2025-06-06","current":-0.549666,"twenty":-7.332589,"median":-4.637737,"eighty":-2.099568,"marketCap":8251593},{"date":"2025-06-13","current":-0.392181,"twenty":-7.316341,"median":-4.63306,"eighty":-2.056833,"marketCap":5887424},{"date":"2025-06-20","current":-0.532797,"twenty":-7.300771,"median":-4.609845,"eighty":-2.053117,"marketCap":7998351},{"date":"2025-06-27","current":-0.511084,"twenty":-7.289347,"median":-4.571286,"eighty":-2.034537,"marketCap":7672399},{"date":"2025-07-03","current":-0.492879,"twenty":-7.259023,"median":-4.506472,"eighty":-1.991406,"marketCap":7399101},{"date":"2025-07-11","current":-0.528288,"twenty":-7.195283,"median":-4.389384,"eighty":-1.94521,"marketCap":7930653},{"date":"2025-07-18","current":-0.557015,"twenty":-7.170822,"median":-4.18175,"eighty":-1.91115,"marketCap":8361912},{"date":"2025-07-25","current":-0.542818,"twenty":-7.116406,"median":-4.001374,"eighty":-1.881987,"marketCap":8148790},{"date":"2025-08-01","current":-0.462648,"twenty":-7.091556,"median":-3.972293,"eighty":-1.853811,"marketCap":6945276},{"date":"2025-08-08","current":-0.502341,"twenty":-7.039039,"median":-3.955696,"eighty":-1.829566,"marketCap":6318446},{"date":"2025-08-15","current":-1.11677,"twenty":-7.015013,"median":-3.928289,"eighty":-1.810366,"marketCap":14046731},{"date":"2025-08-22","current":-1.175134,"twenty":-7.006256,"median":-3.910018,"eighty":-1.798683,"marketCap":14780832},{"date":"2025-08-29","current":-1.08871,"twenty":-6.960631,"median":-3.889463,"eighty":-1.782371,"marketCap":13693798},{"date":"2025-09-05","current":-1.066138,"twenty":-6.940264,"median":-3.868908,"eighty":-1.769697,"marketCap":13409881},{"date":"2025-09-12","current":-0.906383,"twenty":-6.917299,"median":-3.862331,"eighty":-1.745683,"marketCap":11400489},{"date":"2025-09-19","current":-0.936024,"twenty":-6.885877,"median":-3.848353,"eighty":-1.727072,"marketCap":11773310},{"date":"2025-09-26","current":-0.967225,"twenty":-6.839125,"median":-3.809527,"eighty":-1.460474,"marketCap":12165754},{"date":"2025-10-03","current":-1.053027,"twenty":-6.813143,"median":-3.783279,"eighty":-1.137571,"marketCap":13244974},{"date":"2025-10-10","current":-1.237502,"twenty":-6.788993,"median":-3.727307,"eighty":-1.12949,"marketCap":15565298},{"date":"2025-10-17","current":-1.024946,"twenty":-6.76879,"median":-3.686198,"eighty":-1.120137,"marketCap":12891775},{"date":"2025-10-24","current":-0.939534,"twenty":-6.749312,"median":-3.590621,"eighty":-1.104352,"marketCap":11817460},{"date":"2025-10-31","current":-5.148132,"twenty":-6.716708,"median":-3.589534,"eighty":-1.099571,"marketCap":64753209},{"date":"2025-11-07","current":-1.892719,"twenty":-6.656725,"median":-3.544596,"eighty":-1.101463,"marketCap":23806615},{"date":"2025-11-14","current":-2.446921,"twenty":-6.626601,"median":-3.5023,"eighty":-1.103492,"marketCap":28717059},{"date":"2025-11-21","current":-1.944844,"twenty":-6.606869,"median":-3.463472,"eighty":-1.104352,"marketCap":22824686},{"date":"2025-11-28","current":-2.043621,"twenty":-6.587138,"median":-3.425742,"eighty":-1.107316,"marketCap":23983940},{"date":"2025-12-05","current":-2.35582,"twenty":-6.574276,"median":-3.358472,"eighty":-1.113245,"marketCap":27647903},{"date":"2025-12-12","current":-3.019626,"twenty":-6.553045,"median":-3.316207,"eighty":-1.116199,"marketCap":35438329},{"date":"2025-12-19","current":-2.137793,"twenty":-6.527942,"median":-3.243133,"eighty":-1.119015,"marketCap":25089135},{"date":"2025-12-26","current":-2.080983,"twenty":-6.524653,"median":-3.176227,"eighty":-1.123804,"marketCap":24422414},{"date":"2026-01-02","current":-2.099408,"twenty":-6.511499,"median":-3.101522,"eighty":-1.12949,"marketCap":24638648},{"date":"2026-01-09","current":-2.221728,"twenty":-6.504734,"median":-3.060412,"eighty":-1.12949,"marketCap":26074201},{"date":"2026-01-16","current":-2.13984,"twenty":-6.495056,"median":-3.033553,"eighty":-1.130611,"marketCap":25113161},{"date":"2026-01-23","current":-2.069211,"twenty":-6.49239,"median":-3.01718,"eighty":-1.136,"marketCap":24284265},{"date":"2026-01-30","current":-1.919766,"twenty":-6.454926,"median":-3.013363,"eighty":-1.137646,"marketCap":22530368},{"date":"2026-02-06","current":-1.733982,"twenty":-6.428753,"median":-2.969787,"eighty":-1.161067,"marketCap":20350010},{"date":"2026-02-13","current":-1.899293,"twenty":-6.415174,"median":-2.923378,"eighty":-1.169405,"marketCap":22290108},{"date":"2026-02-20","current":-1.407702,"twenty":-6.41284,"median":-2.923378,"eighty":-1.173092,"marketCap":16520786},{"date":"2026-02-27","current":-1.68406,"twenty":-6.373511,"median":-2.907391,"eighty":-1.18307,"marketCap":19764131},{"date":"2026-03-06","current":-1.666788,"twenty":-6.347157,"median":-2.832023,"eighty":-1.198842,"marketCap":19561422},{"date":"2026-03-13","current":-1.602016,"twenty":-6.337936,"median":-2.800625,"eighty":-1.210211,"marketCap":18801263},{"date":"2026-03-20","current":-1.36668,"twenty":-6.318494,"median":-2.717615,"eighty":-1.227754,"marketCap":16039352},{"date":"2026-03-27","current":-1.31918,"twenty":-6.286175,"median":-2.680541,"eighty":-1.251532,"marketCap":15481902},{"date":"2026-04-02","current":-1.245392,"twenty":-6.265359,"median":-2.664029,"eighty":-1.244158,"marketCap":14454023},{"date":"2026-04-10","current":-1.225823,"twenty":-6.247146,"median":-2.620421,"eighty":-1.218208,"marketCap":14226900},{"date":"2026-04-17","current":-1.164532,"twenty":-6.209886,"median":-2.570403,"eighty":-1.20262,"marketCap":13515555},{"date":"2026-04-24","current":-1.166721,"twenty":-6.171236,"median":-2.563437,"eighty":-1.174026,"marketCap":13540960},{"date":"2026-05-01","current":-1.140453,"twenty":-6.122147,"median":-2.524515,"eighty":-1.165408,"marketCap":13236098},{"date":"2026-05-08","current":-1.118563,"twenty":-6.057883,"median":-2.498422,"eighty":-1.149209,"marketCap":12982046},{"date":"2026-05-15","current":-1.214157,"twenty":-6.044513,"median":-2.460923,"eighty":-1.153587,"marketCap":12982976},{"date":"2026-05-22","current":-1.167077,"twenty":-6.017625,"median":-2.414832,"eighty":-1.147254,"marketCap":12479554},{"date":"2026-05-29","current":-1.095219,"twenty":-5.990544,"median":-2.405465,"eighty":-1.145316,"marketCap":11711174},{"date":"2026-06-05","current":-0.98867,"twenty":-5.981753,"median":-2.388873,"eighty":-1.140453,"marketCap":10571852},{"date":"2026-06-12","current":-0.909378,"twenty":-5.96354,"median":-2.368393,"eighty":-1.137422,"marketCap":9723984},{"date":"2026-06-18","current":-0.928913,"twenty":-5.932317,"median":-2.321954,"eighty":-1.136075,"marketCap":9932863},{"date":"2026-06-26","current":-1.031283,"twenty":-5.925812,"median":-2.245526,"eighty":-1.12949,"marketCap":11027505},{"date":"2026-07-02","current":-1.048976,"twenty":-5.920609,"median":-2.230988,"eighty":-1.121618,"marketCap":11216703},{"date":"2026-07-10","current":-1.241078,"twenty":-5.86727,"median":-2.200744,"eighty":-1.121618,"marketCap":13270846},{"date":"2026-07-17","current":-1.23855,"twenty":-5.742138,"median":-2.185308,"eighty":-1.126332,"marketCap":13243818},{"date":"2026-07-24","current":-1.11975,"twenty":-5.616504,"median":-2.175154,"eighty":-1.119513,"marketCap":11973492},{"date":"2026-07-31","current":-1.0237,"twenty":-5.572644,"median":-2.173796,"eighty":-1.117846,"marketCap":10946421},{"date":"2026-08-07","current":-1.074253,"twenty":-5.54114,"median":-2.162275,"eighty":-1.110773,"marketCap":11486985},{"date":"2026-08-14","current":-0.968492,"twenty":-5.510253,"median":-2.155308,"eighty":-1.103492,"marketCap":10811280},{"date":"2026-08-21","current":-1.427269,"twenty":-5.454128,"median":-2.154445,"eighty":-1.104352,"marketCap":15932609},{"date":"2026-08-25","current":-1.389248,"twenty":-5.424948,"median":-2.151584,"eighty":-1.104508,"marketCap":15508175}],"updateTime":1787750606765},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"INTS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660496928","title":"Intensity Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $7 from $5","url":"https://stock-news.laohu8.com/highlight/detail?id=2660496928","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660496928?lang=en_us&edition=fundamental","pubTime":"2026-08-19 00:17","pubTimestamp":1787069841,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nAZN4TEZA8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945149","title":"Oncology Firm Immunome's Q2 Net Loss Widens as R&D Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945149","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945149?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:54","pubTimestamp":1786481686,"startTime":"0","endTime":"0","summary":"Oncology firm Immunome's Q2 net loss widens as R&D costs riseOverviewU.S. targeted oncology firm's Q2 net loss widened as collaboration revenue fell to zeroResearch and development expenses rose sharp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N44811Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4563","BK4139","IMNM","INTS","OLMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658943809","title":"Erasca Q2 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658943809","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658943809?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:13","pubTimestamp":1786479182,"startTime":"0","endTime":"0","summary":"Erasca Q2 net loss widens on higher R&D costsOverviewU.S. oncology drug developer's Q2 net loss widened yr/yr on higher R&D expensesCompany ended Q2 with $384 mln in cash, cash equivalents, and market","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480YC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","INTS","BK4139","OLMA","ERAS","BK4505","STTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658891997","title":"Intensity Therapeutics Q2 Operating Income USD -3.084 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658891997","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658891997?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:31","pubTimestamp":1786447861,"startTime":"0","endTime":"0","summary":"BRIEF-Intensity Therapeutics Q2 Operating Income USD -3.084 MillionAug 11 (Reuters) - Intensity Therapeutics Q2 basic EPS USD -1.11.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXB9RFNZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658920509","title":"Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658920509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658920509?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUA499RJW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992068","title":"Intensity Therapeutics Q2 Basic EPS USD -1.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992068?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXB9RFNZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658411992","title":"Intensity Therapeutics Q2 FY26 Net Loss Widens 18.53% to $3.01 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658411992","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658411992?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:21","pubTimestamp":1786447266,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics Q2 FY26 net loss widens 18.53% to $3.01 millionIntensity Therapeutics posted a GAAP net loss of $3.01 million for the quarter ended June 30, 2026, widening 18.53%.Operating loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL7dVg2n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656555954","title":"Intensity Therapeutics Schedules Q2 Financial Results Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2656555954","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656555954?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:07","pubTimestamp":1785845237,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics schedules Q2 financial results conference callIntensity Therapeutics schedules second-quarter 2026 results release for Aug. 11, 2026, before the market opens.Management to host ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL9lkkkq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651688164","title":"Intensity Therapeutics provides update in Invincicle-4 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2651688164","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651688164?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:50","pubTimestamp":1784116224,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics (INTS) announces that new patients have been administered INT230-6 in the INVINCIBLE-4 Study in Switzerland. The trial analy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-provides-update-in-invincicle-4-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-provides-update-in-invincicle-4-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","INTS","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651450924","title":"Intensity Therapeutics Restarts Phase 2 Invincible-4 Breast Cancer Trial, Doses First Patients in Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2651450924","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651450924?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:45","pubTimestamp":1784115934,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics restarts Phase 2 INVINCIBLE-4 breast cancer trial, doses first patients in SwitzerlandIntensity Therapeutics restarted dosing in its randomized Phase 2 INVINCIBLE-4 presurgical ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL30ZQXx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651903450","title":"Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (invincible-4 Study)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651903450","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651903450?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:45","pubTimestamp":1784115900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nTUA4XZT7S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648486315","title":"Intensity Therapeutics Targets Strategic Partnerships to Accelerate Int230-6 Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2648486315","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648486315?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:07","pubTimestamp":1782907638,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics targets strategic partnerships to accelerate INT230-6 developmentIntensity Therapeutics will resume enrollment in the INVINCIBLE-4 presurgical TNBC study in Q3 2026 in Switzerla","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL92864j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648548348","title":"Intensity Therapeutics Resumes Enrollment in Phase 3 Int230-6 Soft Tissue Sarcoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2648548348","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648548348?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:04","pubTimestamp":1782907448,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics resumes enrollment in Phase 3 INT230-6 soft tissue sarcoma trialIntensity Therapeutics plans to resume enrollment in its Phase 3 INVINCIBLE-3 soft tissue sarcoma trial at a limi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL4bxmZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648867548","title":"Intensity Therapeutics - Advances Late-stage Clinical Studies in Soft Tissue Sarcoma and Presurgical Triple-negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2648867548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648867548?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:00","pubTimestamp":1782907203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nTUA9DPQ6W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648548898","title":"Intensity Therapeutics Provides Mid-year Update Highlighting Late-stage Development Programs and Strategic Partnering Opportunities for Int230-6","url":"https://stock-news.laohu8.com/highlight/detail?id=2648548898","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648548898?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:00","pubTimestamp":1782907203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nTUA9DPQ6W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648510007","title":"Intensity Therapeutics - over 200 Patients Enrolled in Completed Int230-6 Studies with Peer-reviewed Publication","url":"https://stock-news.laohu8.com/highlight/detail?id=2648510007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648510007?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:00","pubTimestamp":1782907203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nTUA9DPQ6W:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644865760","title":"Intensity Therapeutics held annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2644865760","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644865760?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:15","pubTimestamp":1781640954,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics held its annual shareholder meeting on June 16, 2026.Shareholders backed amendments increasing share capacity under the 2021 Stock Incentive Plan by 150,000 shares, subject to implementation.An amendment raising share capacity under the 2024 Employee Stock Purchase Plan by 25,000 shares also cleared, pending execution.Shareholders authorized an adjournment if needed to seek additional support for the meeting’s other items.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL7KFQ2Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633722871","title":"Intensity Therapeutics Q1 FY26 net loss narrows to $2.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633722871","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633722871?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:46","pubTimestamp":1778186790,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics posted a Q1 net loss of USD 2.4 million, narrowing from USD 3.3 million a year earlier; loss per share improved to USD 0.96 from USD 5.51.R&D expense fell to USD 1.2 million from USD 2.2 million, reflecting lower INVINCIBLE-3 trial costs; G&A edged up to USD 1.3 million from USD 1.2 million on an estimated bonus accrual.Cash and cash equivalents declined to USD 10.2 million at March 31 from USD 11.9 million at year-end.INVINCIBLE-4 early TNBC data showed pCR in 5 of 7 patients  receiving INT230-6 before standard of care versus 2 of 6 (33%) on standard of care alone; grade 3+ adverse events were 44% lower in the INT230-6 arm.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL4WgNr3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633179529","title":"BRIEF-Intensity Therapeutics Q1 Operating Income USD -2.526 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633179529","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633179529?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:07","pubTimestamp":1778184435,"startTime":"0","endTime":"0","summary":"BRIEF-Intensity Therapeutics Q1 Operating Income USD -2.526 Million\n\n\nMay 07 (Reuters) - Intensity Therapeutics Q1 basic EPS USD -0.96.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX34BFA8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633762881","title":"Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633762881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633762881?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:06","pubTimestamp":1778184391,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA65VLGR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}